POST #1 – VACCINES OVER VIAGRA?
Vaccines Over Viagra?
Vaccines over Viagra? Health care companies may be incentivized toward neglected public health priorities in the #postCOVID19 world. As many as half of COVID-19 deaths involved secondary bacterial infections. Bacteria complicate viral infections. Yet to date biopharma has had little financial incentive to address antimicrobial resistance. Might that change in the World After? Reimbursement rates for antibiotics are being reviewed in the U.S.; smaller biopharma players may see stronger financial incentives to accelerate their R&D efforts
内嵌的应用
POST #1 – Exhibit 1
50% of patients who have died from COVID-19 had acquired a secondary bacterial infection.
Source: The Lancet
POST #1 – Exhibit 2
As of March 2020, 44 COVID-19 vaccines were in development; only five developers were MSCI ACWI Index constituents.
Source: World Health Organization, MSCI ESG Research LLC.
内嵌的应用
POST #1 – Exhibit 3
Only 9% of health care constituents of the MSCI ACWI IMI have acknowledged antimicrobial resistance as a public health risk.
Source: MSCI ESG Research, as of October 2019
POST #1 – Exhibit 4
Only 39 biopharma companies globally have antibiotics in the regulatory pipeline.
Source: MSCI ESG Research, as of October 2019.
POST #1 – Footnotes
©2020 MSCI Inc. All rights reserved